Innovation you can’t manufacture is just a press release.
AFF portfolio company Antheia just secured a conditional loan commitment of up to $80 million from the Department of War’s Office of Strategic Capital to build domestic manufacturing of critical pharmaceutical ingredients.
Here’s why it matters.
The ingredients in essential medicines are part of the industrial base. Too many of them come from supply chains the United States does not control.
Antheia breaks that dependency. Its biosynthesis platform makes these ingredients through engineered biology — on American soil, at scale.
A breakthrough in the lab is not leadership. Capacity in the field is. Getting there takes strategic capital, patient partners, and a government that treats industrial resilience as national security.
OSC just delivered. So did Antheia.
Proud to back Christina Smolke and her team as they bring critical pharmaceutical manufacturing home.
America can't build the energy transition on a supply chain it doesn't control. Halo Materials reshores high-purity graphite — the critical mineral behind lithium-ion batteries and Gen IV nuclear.
Most essential medicines still start in a farm field, with one harvest a year and a handful of countries growing the crop.
@Antheia rebuilds the plant's chemistry inside yeast. You feed it sugar and get pharmaceutical starting materials back in about 2 weeks, made anywhere.
Portfolio news: Tacta Systems is out of stealth — building robotic hands dexterous enough for the high-value manual work that's resisted automation, powered by dexterous intelligence and large-scale skill capture. Congrats to the team. prnewswire.com/news-releases/…